---
title: "Latigo’s LTG-001 Shows Phase 2 Pain Relief in Tummy Tuck Trial, Positions as Rival to Vertex’s Jou"
id: "stat-news-1-stat-latigo-reports-mid-stage-success-for-would-be-rival-to-vertex-s-pain-drug"
canonical_url: "https://medichelpline.com/clinical-feed/stat-news-1-stat-latigo-reports-mid-stage-success-for-would-be-rival-to-vertex-s-pain-drug"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "STAT News"
source_url: "https://www.statnews.com/2026/07/29/latigo-phase-2-results-non-opioid-pain-reliever-ltg-001/?utm_campaign=rss"
published_at: "2026-07-29T21:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Latigo’s LTG-001 Shows Phase 2 Pain Relief in Tummy Tuck Trial, Positions as Rival to Vertex’s Jou
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/stat-news-1-stat-latigo-reports-mid-stage-success-for-would-be-rival-to-vertex-s-pain-drug
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** STAT News
- **Source URL:** [Original Journal Publication](https://www.statnews.com/2026/07/29/latigo-phase-2-results-non-opioid-pain-reliever-ltg-001/?utm_campaign=rss)
- **Published At:** 2026-07-29T21:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Latigo Biotherapeutics reported positive **Phase 2** results for its oral non-opioid investigational drug **LTG-001** in a trial of patients after tummy tuck surgery. - The randomized trial enrolled 343 patients and compared high and low doses of LTG-001, placebo, and a combination of acetaminophen plus hydrocodone. Exact dose levels and statistical values were not reported in the source. - Patients receiving either dose of LTG-001 experienced **statistically significant pain relief versus placebo at 48 hours** post-surgery, according to the company’s report. - Participants in all study arms could use oxycodone as rescue medication; those on the high dose of LTG-001 were **significantly less likely** to use rescue oxycodone than placebo recipients. - Overall safety was described as generally favorable and well tolerated. The placebo group had higher overall adverse event rates, but some specific adverse events were more common with LTG-001. - Reported adverse events more frequent in the LTG-001 high-dose group included **fever** (7% vs. 2% for placebo) and **lightheadedness** (6% vs. 1% for placebo). - The results were presented by Latigo and reported by STAT; additional methodological details, full safety tables, efficacy magnitudes, and longer-term outcomes were not reported in the source article. - The development is presented in the context of a broader industry race for **non-opioid pain** therapies and as a potential competitor to Vertex’s marketed pain drug Journavx. - The article originated as a STAT+ exclusive; some content beyond what was summarized may be behind the STAT+ paywall and was not provided in the source text.
## Clinical Analysis & Structured Key Points
[Skip to Main Content](https://www.statnews.com/2026/07/29/latigo-phase-2-results-non-opioid-pain-reliever-ltg-001/?utm_campaign=rss#wrapper) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/STAT10-Years-White.svg) ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-10.svg) ](https://www.statnews.com/) * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/07/29/latigo-phase-2-results-non-opioid-pain-reliever-ltg-001/?utm_campaign=rss) [Congress](https://www.statnews.com/topic/congress/) [Covid-19](https://www.statnews.com/topic/covid-19/) [FDA](https://www.statnews.com/topic/fda/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) My Account * [Settings Complete your personal information for a more tailored experience ](https://www.statnews.com/my-account/) * [Billing](https://www.statnews.com/my-account/billing/) * [Log In](https://www.statnews.com/login/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-10.svg) A decade of reporting from the frontiers of health and medicine ](https://www.statnews.com/) * [Newsletters](https://www.statnews.com/signup/) * [Log In](https://www.statnews.com/login/) * [My Account](https://www.statnews.com/my-account/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Public Health](https://www.statnews.com/category/health/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Policy](https://www.statnews.com/category/politics/) * [Science](https://www.statnews.com/category/in-the-lab/) * [First Opinion](https://www.statnews.com/category/first-opinion/) * [STAT+](https://www.statnews.com/topic/stat-plus/) * [STAT Events](https://www.statnews.com/events/) [ ![STAT](https://www.statnews.com/wp-content/themes/stat/images/stat-logo-10.svg) ](https://www.statnews.com/) Search * [Log In](https://www.statnews.com/login/) * [Subscribe Now](https://www.statnews.com/stat-plus/) * [My Account](https://www.statnews.com/my-account/) [Home](https://www.statnews.com/) News * [Latest](https://www.statnews.com/latest/) * [Series & Investigations](https://www.statnews.com/stat-series-and-investigations-award-winning-journalism/) * Business * [Biotech](https://www.statnews.com/category/biotech/) * [Pharma](https://www.statnews.com/category/pharma/) * [Health Tech](https://www.statnews.com/category/health-tech/) * [Health Insurance](https://www.statnews.com/category/insurance/) * [Hospitals](https://www.statnews.com/category/hospitals/) * [Medical Devices](https://www.statnews.com/topic/medical-devices/) * Washington * [Policy](https://www.statnews.com/category/politics/) * [FDA](https://www.statnews.com/topic/fda/) * [NIH](https://www.statnews.com/topic/nih/) * Science * [CRISPR](https://www.statnews.com/topic/crispr/) * [Gene Therapy](https://www.statnews.com/topic/gene-therapy/) * [Neuroscience](https://www.statnews.com/topic/neuroscience/) * Public Health * [Addiction](https://www.statnews.com/topic/addiction/) * [Covid-19](https://www.statnews.com/topic/coronavirus/) * [Abortion](https://www.statnews.com/topic/abortion/) * [Health Disparities](https://www.statnews.com/topic/health-disparities/) * [Infectious Disease](https://www.statnews.com/topic/infectious-disease/) * [Mental Health](https://www.statnews.com/topic/mental-health/) * Disease * [Cancer](https://www.statnews.com/topic/cancer/) * [Cardiovascular Disease](https://www.statnews.com/topic/cardiovascular-disease/) * [Chronic Disease](https://www.statnews.com/topic/chronic-disease/) * [Diabetes](https://www.statnews.com/topic/diabetes/) * [Alzheimer's](https://www.statnews.com/topic/alzheimers/) * [Obesity](https://www.statnews.com/topic/obesity/) * Features * [Health Care Costs](https://www.statnews.com/health-insurance-costs-out-of-pocket-out-of-reach-series/) * [The Deadliest Drug](https://www.statnews.com/alcohol-epidemic-hiding-plain-sight-deadliest-drug-series/) * [Science, Shattered](https://www.statnews.com/american-science-shattered/) [Newsletters](https://www.statnews.com/signup/) [Opinion](https://www.statnews.com/category/first-opinion/) Columns * [Adam Feuerstein](https://www.statnews.com/category/adams-take/) * [Matthew Herper](https://www.statnews.com/category/matts-take/) * [Ed Silverman](https://www.statnews.com/category/pharmalot-view/) [Reports](https://reports.statnews.com/) [E-books](https://www.statnews.com/ebooks/) [Podcasts](https://www.statnews.com/podcasts/) [Tools & Trackers](https://www.statnews.com/trackers/) * [CRISPR Tracker](https://www.statnews.com/feature/crispr/tracker/) * [Breakthrough Device Tracker](https://www.statnews.com/feature/stat-plus/breakthrough-device-designation-fda-tracker/) * [Generative AI Tracker](https://www.statnews.com/feature/stat-plus/generative-ai-health-hospitals-tracker/) * [Obesity Drug Tracker](https://www.statnews.com/2023/09/12/new-weight-loss-drug-tracker-novo-nordisk-eli-lilly/) [Events](https://www.statnews.com/events/) * [Upcoming Events](https://www.statnews.com/events#upcoming-events) * [Summits](https://www.statnews.com/stat-summits/) [Community](https://www.statnews.com/community/) * [STAT Wunderkinds 2026](https://www.statnews.com/wunderkinds-nominate/) [Video](https://youtube.com/@Statnews) [Advertise](https://www.statnews.com/advertise/) * [STAT Brand Studio](https://sbs.statnews.com/) What's the word? Test your knowledge with our new weekday mini crossword [ Start solving ](https://www.statnews.com/stat-mini-crossword/) [STAT Plus](https://www.statnews.com/stat-plus/)[Biotech](https://www.statnews.com/category/biotech/) # Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx ## Tummy tuck patients reported post-surgery pain relief with biotech’s non-opioid pill * [Manage alerts for this article](https://www.statnews.com/my-account/edit/#emails) * Email this article * [Share this article](https://www.statnews.com/2026/07/29/latigo-phase-2-results-non-opioid-pain-reliever-ltg-001/?utm_campaign=rss) ![](https://www.statnews.com/wp-content/uploads/2026/07/AdobeStock_613796267-645x645.jpeg) Adobe ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) By [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) July 29, 2026 West Coast Biotech & Life Sciences Reporter ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) 1. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") 2. [](https://x.com/JonathanWosen "X") jonathan.wosen@statnews.com Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. For decades, efforts to develop non-opioid pain drugs were marked by failure. But what was once a graveyard of drug discovery is quickly turning into a race for a multibillion-dollar market, with Latigo Biotherapeutics publishing positive data on Wednesday for a therapy meant to rival a Vertex medicine already on the market. The startup’s Phase 2 trial enrolled 343 patients who’d gotten tummy tuck surgery; they were randomized to receive a high or low dose of Latigo’s experimental pill, a placebo, or a combination of acetaminophen and the opioid hydrocodone. Those given either dose of Latigo’s oral drug, LTG-001, showed statistically significant pain relief compared to placebo after 48 hours. And while participants in all groups had the option to use the opioid oxycodone if they needed additional pain management, those on a high dose of Latigo’s therapy were significantly less likely to do so than participants on placebo. Advertisement The drug was generally safe and well tolerated, with higher overall adverse event rates in the placebo group than in either treatment group. Some adverse events, however, were more common in the treatment groups: 7% of those taking a high dose of LTG-001 had a fever, compared with 2% of people on placebo, and 6% experienced lightheadedness, compared with 1% of the placebo group. STAT+ Exclusive Story Already have an account? [Log in](https://www.statnews.com/login/) ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-breaker-bg.png) [ ![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo-white.svg) ](https://www.statnews.com/stat-plus/) ## This article is exclusive to STAT+ subscribers ### Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? [Log in](https://www.statnews.com/login/) Individual plans Group plans Monthly $39 Totals $468 per year [$39/month](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-monthly-39-0) Totals $468 per year Starter $30 for 3 months, then $399/year [$30 for 3 months](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=3mo30_yearly_pw) Then $399/year Annual $399 Save 15% [$399/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat-plus-annually-399-0) Save 15% 11+ Users Custom Savings start at 25%! [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) [Request A Quote](https://www.statnews.com/stat-plus/group-subscriptions/) Savings start at 25%! 2-10 Users $300 Annually per user [$300/year](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) [Get Started](https://www.statnews.com/stat-plus/subscribe/?plan=stat_plus_groups_self_serve_0) $300 Annually per user [View All Plans](https://www.statnews.com/stat-plus/) [![STAT+](https://www.statnews.com/wp-content/themes/stat/images/stat-plus-logo.svg)](https://www.statnews.com/stat-plus/) To read the rest of this story subscribe to STAT+. [Subscribe](https://www.statnews.com/stat-plus/) [Log In](https://www.statnews.com/login/) [drug development](https://www.statnews.com/topic/drug-development/), [pain](https://www.statnews.com/topic/pain/), [research](https://www.statnews.com/topic/research/), [STAT+](https://www.statnews.com/topic/stat-plus/), [Vertex](https://www.statnews.com/topic/vertex/) [Submit a correction request](https://www.statnews.com/contact/?how_can_we_help_=Editorial%20Correction%20Request)[Reprints](https://www.parsintl.com/publications/stat/) 1. ![](https://www.statnews.com/wp-content/uploads/2022/01/jonathan-w-avatar-round-80x80.png) [Jonathan Wosen](https://www.statnews.com/staff/jonathan-wosen/) 1. [](https://x.com/JonathanWosen "X") 2. 3. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") West Coast Biotech & Life Sciences Reporter 1. [](https://x.com/JonathanWosen "X") 2. 3. [](https://www.linkedin.com/in/jonathan-wosen-phd-b69172147/ "Linkedin") Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. ![](https://www.statnews.com/wp-content/themes/stat/images/article-new/envelope-open.svg) ![](https://www.statnews.com/wp-content/uploads/2023/06/Morning-Rounds-Logo-Black-640x295.png) ### Newsletter Understand how science, health policy, and medicine shape the world every day Please enter a valid email address. Sign Up Your data will be processed in accordance with our [Privacy Policy](https://www.statnews.com/privacy/) and [Terms of Service](https://www.statnews.com/terms-conditions/). You may opt out of receiving STAT communications at any time. Advertisement Most Popular 1. ![](https://www.statnews.com/wp-content/uploads/2026/07/Duchenne-muscular-dystrophy-1_LiveBlog-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [FDA expert committee reviews Capricor Therapeutics’ Duchenne drug](https://www.statnews.com/2026/07/29/capricor-therapeutics-deramiocel-fda-review-meeting-live-blog/) 2. ![](https://www.statnews.com/wp-content/uploads/2026/07/fischer-3-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In the biotech industry, a most-wanted fugitive was long hiding in plain sight](https://www.statnews.com/2026/07/29/ronald-fischer-fugitive-used-alias-forged-cv-held-biotech-executive-jobs/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/07/AP26210452356034-80x80.jpg) [Fauci invokes Fifth Amendment in declining to answer questions before Senate panel](https://www.statnews.com/2026/07/29/fauci-pleads-fifth-criticizes-rand-paul-senate-hearing/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/07/doctors-llms-1-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Clinical chatbots are taking medicine by storm. Should doctors trust them?](https://www.statnews.com/2026/07/29/clinical-ai-vs-generalist-llm-benchmark-study-trust-accuracy-safety/) 5. ![](https://www.statnews.com/wp-content/uploads/2026/06/conference-center-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [American Diabetes Association, facing calls for resignations, asks for patience](https://www.statnews.com/2026/07/28/american-diabetes-association-fallout-researchers-expulsion/) #### [ Reports ](https://reports.statnews.com/) [ ![](https://www.statnews.com/wp-content/uploads/2025/08/VCFirms2025_LeftRailUnit-328x426.png) 2025 Edition: Ranking Biotech’s Top Venture Capital Firms ](https://reports.statnews.com/products/biotech-top-venture-capital-firms-2025) Advertisement #### [Events](https://www.statnews.com/events/) [ ![](https://www.statnews.com/wp-content/uploads/2026/06/2026AAIC_Wordpress_CalendarImage-80x80.jpg) AAIC Recap: What’s Next in Alzheimer’s Virtual Jul 16 ](https://www.statnews.com/event/2026-aaic-recap-alzheimers-conference/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_OfficeHours_VirtualEvent_Wordpress_CalendarImage-1-80x80.jpg) Office Hours with STAT’s Bob Herman Virtual Jul 22 ](https://www.statnews.com/event/out-of-pocket-series-bob-herman-office-hours-ama-july-2026/) [ ![](https://www.statnews.com/wp-content/uploads/2026/07/2026_DD_OfficeHours_VirtualEvent_Wordpress_CalendarImage-80x80.jpg) Office Hours with Isabella Cueto and Lev Facher Virtual Jul 29 ](https://www.statnews.com/event/deadliest-drug-series-office-hours-ama-july-2026/) Most Read in [STAT+](https://www.statnews.com/stat-plus/) 1. ![](https://www.statnews.com/wp-content/uploads/2026/07/prima-implant-2026-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [‘Cochlear implant for blindness’ debuts in Europe, could launch in U.S. in 2027](https://www.statnews.com/2026/07/22/prima-retinal-implant-for-macular-degeneration-us-timeline/) 2. ![](https://www.statnews.com/wp-content/uploads/2025/09/TheWorkup_Illustration_MollyFerguson_093025-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer](https://www.statnews.com/2026/07/22/lipfendra-enlicitide-merck-cholesterol-barriers/) 3. ![](https://www.statnews.com/wp-content/uploads/2026/07/AdobeStock_419763193-80x80.jpeg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [In win for RFK Jr., FDA advisory panel narrowly votes to allow compounding of unapproved peptides](https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/) 4. ![](https://www.statnews.com/wp-content/uploads/2026/07/MUGSHOT_01-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [A most-wanted fugitive appears to have been secretly working as a biotech executive](https://www.statnews.com/2026/07/20/ronald-fischer-rhode-island-fugitive-richard-graydon-biotech/) 5. ![](https://www.statnews.com/wp-content/uploads/2025/09/GettyImages-1227710420-80x80.jpg) ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug](https://www.statnews.com/2026/07/27/fda-efficacy-doubts-capricor-therapeutics-duchenne-muscular-dystrophy/) #### Recommended ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Live Updates Live Updates July 29, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA expert committee reviews Capricor Therapeutics’ Duchenne drug ](https://www.statnews.com/2026/07/29/capricor-therapeutics-deramiocel-fda-review-meeting-live-blog/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) and [Andrew Joseph](https://www.statnews.com/staff/andrew-joseph/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech July 29, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: In the biotech industry, a most-wanted fugitive was long hiding in plain sight ](https://www.statnews.com/2026/07/29/ronald-fischer-fugitive-used-alias-forged-cv-held-biotech-executive-jobs/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) Advertisement ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) First Opinion First Opinion July 29, 2026 ### [ The VA could help America win the biotechnology race with China ](https://www.statnews.com/2026/07/29/biotech-race-china-veterans-affairs-va/) By David Shulkin ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech July 28, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA staff reiterate concerns about Replimune skin cancer treatment ](https://www.statnews.com/2026/07/28/replimune-rp1-skin-cancer-fda-staff-analysis/) By [Elaine Chen](https://www.statnews.com/staff/elaine-chen/) and [Matthew Herper](https://www.statnews.com/staff/matthew-herper/) ![](https://www.statnews.com/wp-content/plugins/stat-lazy-load/images/328x185-00000000.png) Biotech Biotech July 28, 2026 ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Preliminary trial results suggest a path to a safer Alzheimer’s treatment ](https://www.statnews.com/2026/07/28/promis-neurosciences-amyloid-alzheimers-aria/) By [Adam Feuerstein](https://www.statnews.com/staff/adam-feuerstein/) #### Subscriber Picks 1. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: Ahead of hearing, FDA questions the efficacy of Capricor's Duchenne drug ](https://www.statnews.com/2026/07/27/fda-efficacy-doubts-capricor-therapeutics-duchenne-muscular-dystrophy/) By [Jason Mast](https://www.statnews.com/staff/jason-mast/) 2. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: I’m a cardiologist. I’m not sure the new cholesterol drug enlicitide is a game-changer ](https://www.statnews.com/2026/07/22/lipfendra-enlicitide-merck-cholesterol-barriers/) By Vishal Khetpal 3. ### ![](https://www.statnews.com/wp-content/themes/stat/images/home/statplus.svg) [ STAT Plus: FDA expert committee reviews Capricor Therapeutics’ Duc
## Related Clinical Research

- [Most-favored nation pharma deals target Medicaid but exempt Medicare, analysts say](https://medichelpline.com/clinical-feed/stat-news-0-stat-how-trump-s-latest-pharma-deals-may-undermine-efforts-to-rein-in-drug-costs.md)
- [Analysis: Five key questions about Trump’s latest drugmaker deals and what's still unknown](https://medichelpline.com/clinical-feed/stat-news-0-stat-5-burning-questions-on-trump-s-latest-deals-with-drugmakers.md)
- [Cardiac-targeted delivery strategies for advanced therapies in heart disease](https://medichelpline.com/clinical-feed/pubmed-42284133.md) (DOI: 10.1093/eurheartj/ehag432)
- [Waist circumference predicts mortality more than BMI in adults 65+: study findings](https://medichelpline.com/clinical-feed/medical-news-today-0-bmi-vs-waist-size-study-finds-belly-fat-matters-more-than-weight-for-death-risk.md)
- [Keto Diet Shows Superior Metabolic Benefits Over Mediterranean and Low-Fat Diets](https://medichelpline.com/clinical-feed/medical-news-today-1-keto-diet-may-have-metabolic-advantages-over-mediterranean-low-fat-diets.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.